Last updated on June 2020

Investigating Safety Tolerability Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours

Brief description of study

A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents with solid tumours.

Detailed Study Description

A Phase I open-label, multicentre study to determine the RP2D of olaparib monotherapy in the paediatric population, and to evaluate the safety, tolerability, PK, PDx and preliminary efficacy of olaparib monotherapy in paediatric patients from 6 months to <18 years of age at enrolment, with relapsed or refractory non-CNS solid tumours for whom there are no standard treatment options. It is anticipated that eligible patients fulfilling all of the inclusion criteria and none of the exclusion criteria, will include but will not be limited to those with osteosarcoma, rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, Ewing Sarcoma and neuroblastoma.

Clinical Study Identifier: NCT04236414

Find a site near you

Start Over

Research Site

Petah Tikva, Israel
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.